Page last updated: 2024-11-02

pirenzepine and Lymphoma, Non-Hodgkin

pirenzepine has been researched along with Lymphoma, Non-Hodgkin in 1 studies

Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.

Lymphoma, Non-Hodgkin: Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Passik, SD1
Cooper, M1

Other Studies

1 other study available for pirenzepine and Lymphoma, Non-Hodgkin

ArticleYear
Complicated delirium in a cancer patient successfully treated with olanzapine.
    Journal of pain and symptom management, 1999, Volume: 17, Issue:3

    Topics: Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; Humans; Lymphoma, Non-Hodgkin; Middle Ag

1999